FGFR mutants including at least the mutation FGFR3 L608F; or one or more FGFR mutants including at least the fusion FGFR2-TACC2 is detected. In one aspect, disclosed herein is the use of erdafitinib in the manufacture of a medicament for the treatment of cholangiocarcinoma in a patient wherein the patient is identified as being responsive to the treatment with erdafitinib by evaluating a biological sample that had been obtained from the patient for the presence of one or more FGFR fusions including at least the fusion FGFR2-TACC2; or one or more FGFR mutants including at least the mutation FGFR3 L608F, wherein the presence of one or more FGFR fusions including at least the fusion FGFR2-TACC2; or one or more FGFR mutants including at least the mutation FGFR3 L608F is detected.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0016] Reference to a particular numerical value includes at least that particular value, unless the context clearly dictates otherwise. When a range of values is expressed, another embodiment includes from the one particular value and/or to the other particular value. Further, reference to values stated in ranges include each and every value within that range. All ranges are inclusive and combinable.

[0017] The following abbreviations are used throughout the specification: FGFR (fibroblast growth factor receptor); FFPET (Formalin-Fixed Paraffin-Embedded Tissue); SNP (single nucleotide polymorphism).

[0018] As used herein, “treating” and like terms refer to reducing the severity and/or frequency of cancer symptoms, eliminating cancer symptoms and/or the underlying cause of said symptoms, reducing the frequency or likelihood of cancer symptoms and/or their underlying cause, and improving or remediating damage caused, directly or indirectly, by cancer.

[0019] “Biological samples” refers to any sample from a patient in which cancerous cells can be obtained and detection of a FGFR mutant is possible. Suitable biological samples include, but are not limited to, blood, lymph fluid, bone marrow, a solid tumor sample, or any combination thereof. In some embodiments, the biological sample can be FFPET.

CLAIMS

1. Use of erdafitinib in the manufacture of a medicament for the treatment of cholangiocarcinoma in a patient wherein the patient is identified as being responsive to the treatment with erdafitinib by evaluating a biological sample that had been obtained from the patient for the presence of one or more FGFR fusions including at least the fusion FGFR2-TACC2; or one or more FGFR mutants including at least the mutation FGFR3 L608F, wherein the presence of one or more FGFR fusions including at least the fusion FGFR2-TACC2; or one or more FGFR mutants including at least the mutation FGFR3 L608F is detected.
2. The use according to claim 1 wherein the erdafitinib is to be administered at a dose of 8 mg once daily.
3. The use according to claim 1 wherein the erdafitinib is to be administered at a dose of 9 mg once daily.
4. The use according to claim 1 wherein the erdafitinib is to be administered at a dose of 8 mg, in particular 8 mg once daily, with an option to uptitrate to 9 mg when serum phosphate levels are < 5.5 mg/dL, or are < 7 mg/dL or range from and include 7 mg/dL to ≤9 mg/dL or are ≤9 mg/dL, and depending on treatment-related adverse events observed.
5. The use according to claim 4 wherein the levels of serum phosphate for determining whether or not to up-titrate are to be measured on a treatment day during the first cycle of erdafitinib treatment.
6. The use according to claim 5 wherein the levels of serum phosphate for determining whether or not to up-titrate are to be measured on day 14 ± 2 days of erdafitinib administration.
7. The use according to claim 6 wherein the levels of serum phosphate for determining whether or not to up-titrate are to be measured on day 14 of erdafitinib administration.
8. The use according to any one of claims 1 to 7 wherein the fusion FGFR2-TACC2 is detected.
9. The use according to any one of claims 1 to 7 wherein the mutation FGFR3 L608F is detected.
10. The use according to any one of claims 1 to 9 wherein the patient is an Asian patient.